A multi-centre, retrospective study to determine the sequence of 2nd generation (2G) TKIs (nilotinib, dasatinib, bosutinib) in patients with chronic-phase Philadelphia chromosome–positive chronic-phase myeloid leukaemia
Latest Information Update: 06 Dec 2019
At a glance
- Drugs Bosutinib (Primary) ; Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 06 Dec 2019 New trial record
- 06 Nov 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology